For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …

Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …

Abstract Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other
second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has …

BACKGROUND Nature has evolved elegant mechanisms to regulate the physical distance
between molecules, or proximity, for a wide variety of purposes. Whether it is activation of …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Abstract Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging
alternative therapeutic strategy with the potential to address many of the challenges …